We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
(-0.32%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$60.5M |
| 2 |
S&P Global
SPGI
|
+$52.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$41.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$38.2M |
| 5 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$98.3M |
| 2 |
Eli Lilly
LLY
|
+$54.1M |
| 3 |
Apple
AAPL
|
+$51.2M |
| 4 |
Fidelity National Information Services
FIS
|
+$42.9M |
| 5 |
Stryker
SYK
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Financials | 21.66% |
| 3 | Technology | 21.39% |
| 4 | Communication Services | 9.45% |
| 5 | Consumer Discretionary | 5.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$211B
| $52.8M | 1% |
357,021
+121,975
| +52% | +$18M |
|
27
Alibaba
BABA
$269B
| $52.5M | 0.99% |
660,050
+67,830
| +11% | +$5.31M |
|
|
28
S&P Global
SPGI
$126B
| $52.2M | 0.99% |
+487,049
| New | +$52.3M |
|
|
29
Bristol-Myers Squibb
BMY
$127B
| $51.9M | 0.98% |
705,000
+585,000
| +488% | +$41.3M |
|
30
Union Pacific
UNP
$183B
| $49M | 0.93% |
561,835
-41,169
| -7% | -$3.48M |
|
31
Aecom
ACM
$9.07B
| $48.4M | 0.91% |
1,522,258
-306,293
| -17% | -$9.69M |
|
|
MRSH
32
Marsh
MRSH
$86.3B
| $47.6M | 0.9% |
695,000
| – | – |
|
33
UnitedHealth
UNH
$382B
| $44.9M | 0.85% |
318,000
+64,461
| +25% | +$8.59M |
|
34
McKesson
MCK
$98.5B
| $44.8M | 0.85% |
240,235
-5,599
| -2% | -$982K |
|
35
Icon
ICLR
$12.8B
| $44.7M | 0.84% |
638,166
-23,765
| -4% | -$1.63M |
|
36
Accenture
ACN
$89.9B
| $44.1M | 0.83% |
389,610
-105,579
| -21% | -$12.2M |
|
|
AGN
37
DELISTED
Allergan plc
AGN
| $39.6M | 0.75% |
171,500
+165,718
| +2,866% | +$38.2M |
|
|
SPLK
38
DELISTED
Splunk Inc
SPLK
| $37.4M | 0.71% |
691,117
-100,253
| -13% | -$5.29M |
|
39
Aon
AON
$77.3B
| $36.6M | 0.69% |
334,823
-142,029
| -30% | -$15M |
|
|
QVCGA
40
DELISTED
QVC Group Inc Series A
QVCGA
| $36.4M | 0.69% |
29,578
-17,062
| -37% | -$21.4M |
|
|
MDSO
41
DELISTED
Medidata Solutions, Inc.
MDSO
| $33.2M | 0.63% |
709,386
+120,621
| +20% | +$5.26M |
|
42
Salesforce
CRM
$134B
| $33.2M | 0.63% |
417,709
+82,394
| +25% | +$6.47M |
|
43
CALL
Advanced Micro Devices
AMD
$851B
| $32M | 0.6% |
+6,231,700
| New | +$24.2M |
|
|
CYBR
44
DELISTED
CyberArk
CYBR
| $31.8M | 0.6% |
653,921
+84,609
| +15% | +$3.66M |
|
45
CALL
Microsoft
MSFT
$2.84T
| $31.7M | 0.6% |
+620,000
| New | +$32.2M |
|
|
PFPT
46
DELISTED
Proofpoint, Inc.
PFPT
| $31.3M | 0.59% |
496,575
-45,187
| -8% | -$2.58M |
|
|
N
47
DELISTED
Netsuite Inc
N
| $31.3M | 0.59% |
429,263
+41,012
| +11% | +$3.14M |
|
48
Cigna
CI
$76.6B
| $31.1M | 0.59% |
243,028
+64,988
| +37% | +$8.58M |
|
49
eBay
EBAY
$48.6B
| $30.7M | 0.58% |
1,310,877
-721,562
| -36% | -$17.4M |
|
50
Danaher
DHR
$135B
| $30.3M | 0.57% |
446,350
| – | – |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.
- Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
- Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
- Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
- Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
- Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
- Polar Capital opened 35 new positions and closed 35 in Q2 2016.
- Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.
Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.